Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial

Reich, Kristian; Nestle, Frank O.; Papp, Kim; Jp, Ortonne; Wu, Yi-Ming; Bala, Mohan; Evans, Robert J.; Guzzo, Cynthia; Li, S; Dooley, Lisa T.; Griffiths, C.E.M.

doi:10.1111/j.1365-2133.2006.07237.x

Cited by 116 publications

(110 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HRQoL, as assessed by the DLQI, was significantly improved in infliximab patients compared with placebo-treated patients. 7,9,13 This is important because plaque psoriasis has been linked to depression and suicidal tendencies.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

Barker

Hoffmann²,

Wozel

et al. 2011

British Journal of Dermatology

Self Cite

178

121

View full text Add to dashboard Cite

Conflicts of interestSee Appendix 1. DOI 10.1111/j. 1365-2133.2011.10615.x SummaryBackground Infliximab is indicated for treatment of moderate-to-severe plaque psoriasis in adults whose disease cannot be controlled with other systemic therapies, including methotrexate (MTX). To date, no studies have directly compared the efficacy and safety of infliximab and MTX. Objectives To compare the efficacy and safety of infliximab vs. MTX in adults with moderate-to-severe plaque psoriasis. Methods MTX-naïve patients (n = 868) were randomized 3 : 1 to receive infliximab 5 mg kg )1 at weeks 0, 2, 6, 14 and 22 or MTX 15 mg weekly with a dose

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

Barker

Hoffmann²,

Wozel

et al. 2011

British Journal of Dermatology

Self Cite

178

121

View full text Add to dashboard Cite

show abstract

“…These measures led to a significant improvement in the quality of life of patients and allowed many of them to return to normal life 13,[22][23][24][25] . The paper presents an assessment of our own experience with individual methods of systemic treatment of psoriasis in patients who were subject to clinical and laboratory follow-up in the specialized Counseling Centre at the Department of Dermatology for at least 24 weeks.…”

Section: Discussionmentioning

confidence: 99%

Experience with the systemic treatment of severe forms of psoriasis

Tichý¹,

Zapletalová²

2012

BIOMED PAP

View full text Add to dashboard Cite

Introduction. Severe forms of psoriasis are indicated for systemic treatment with conventional and biological preparations . The former includes methotrexate, cyclosporin, acitretin and narrow-band ultraviolet B phototherapy but toxicity may limit the dose and duration of treatment. Currently used less toxic biological preparations include inhibitors of TNF-alpha (etanercept, adalimumab, infliximab) and the monoclonal antibody against IL 12/23 ustekinumab. We present our own more than five-year experience with the systemic treatment of severe forms of psoriasis using these preparations. Methods. A total of 66 patients treated with systemic therapy (except for phototherapy) were divided into groups based on treatment. Therapeutic doses were administered according to the recommendations of the manufacturer and dermatological societies. Standard PASI and BSA indexes were used to evaluate clinical condition at weeks 0, 12 and 24. Results. Differences in PASI score reduction and BSA index between patient groups treated with different preparations were statistically significant at monitored intervals. At week 12, PASI score was reduced by 75% or more in a significantly greater number of patients treated with infliximab + methotrexate than those treated with acitretin. At week 24, identical comparison showed a significantly greater number of patients treated with etanercept or adalimumab than those receiving methotrexate. For BSA index reduction by 50% or more, no statistically significant differences were found between patient groups during the follow-up period. Conclusion. Systemic therapy provides a significant benefit to patients with severe psoriasis. Biological preparations are more effective than conventional medications which are often limited by severe side-effects and generally less tolerated than biological treatments.

show abstract

“…The DLQI index decreased 87% in the infliximab group versus 3% for placebo. A significant improvement was seen in all 8 SF36 subscales for infliximab compared to placebo [54].…”

Section: Efficacy Infliximabmentioning

confidence: 89%

Biologicals in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method

Janknegt¹

2016

J Pharma Care Health Sys

View full text Add to dashboard Cite

The treatment of plaque psoriasis is changing because of the introduction of new treatment options. The goal of this article is to allow a transparent and rational choice of medicines by means of the System of Objectified Judgement Analysis. The following selection criteria (relative weight) were applied: approved indications (40), drug interactions (60), clinical efficacy (400), safety (300), dosage frequency (100) and documentation (100). Acquisition cost was not taken into consideration to allow a preselection on quality aspects only. Adalimumab, etanercept, infliximab and ustekinumab were compared on these criteria. Infliximab and ustekinumab showed the highest scores and are the most suitable medicines for the treatment of severe plaque psoriasis. Of course, cost will play a key role in the final selection in individual hospitals. Weight Approved indications 40 Drug Interactions 60Clinical efficacy 400Safety 300Dosage frequency 100 Documentation 100Total 1000 Selection Criteria Approved IndicationsThe number of licensed indications is a good measure of the applicability and documentation of the drugs. Although this analysis is limited to the treatment of plaque psoriasis, the fact that a drug is approved for (almost) all indications listed below is, from a formulary point of view, advantageous to another drug, which is approved for only one or two applications.The percentage of the maximum score for approved indications was obtained as follows (Table 2): IndicationMaximum Score (%)Plaque psoriasis 50% Psoriatric arthritis 20%Rheumatoid arthritis 10% Spondylitis ankylopoetica 10%Inflammatory bowel disease 10% Drug interactionsInteractions play a role only in patients who use other drugs which may interact with biologicals. However, it is a relevant criterion from a formulary point of view.The score for each drug was dependent on the frequency and severity of observed drug interactions. Clinical efficacyClinical efficacy is always a very important selection criterion for any group of drugs. The score for each drug was derived from the results of double-blind comparative studies. SafetyThe extent and the severity of adverse effects is another important selection criterion for drugs. A distinction was made between "minor" side effects, such as gastrointestinal disturbances or skin reactions, occurring in clinical trials and severe or even life-threatening adverse reactions observed with large scale use of the drugs. The evaluation of the "minor" adverse effects was based on results of double blind comparative clinical studies.

show abstract

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial

Abstract: Infliximab induction and maintenance regimens resulted in rapid, substantial, sustained and clinically meaningful improvement in both dermatology-specific and general quality of life indices in patients with psoriasis, with total clearance resulting in maximum improvement.

Cited by 116 publications

References 30 publications

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

Experience with the systemic treatment of severe forms of psoriasis

Biologicals in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method

Contact Info

Product

Resources

About